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Background: The bone marrow (BM) is a main risk organ during Lu-177-PSMA ligand therapy of metastasized castration-
resistant prostate cancer (mCRPC) patients. So far, BM dosimetry relies on S values, which are pre-computed for reference
anatomies, simplified activity distributions, and a physiological BM distribution. However, mCRPC patients may show a
considerable bone lesion load, which leads to a heterogeneous and patient-specific activity accumulation close to BM-
bearing sites. Furthermore, the patient-specific BM distribution might be significantly altered in the presence of bone
lesions. The aim was to perform BM absorbed dose calculations through Monte Carlo (MC) simulations and to investigate
the potential value of image-based BM localization.
This study is based on 11 Lu-177-PSMA-617 therapy cycles of 10 patients (10 first cycles), who obtained a pre-therapeutic
Ga-68-PSMA-11 PET/CT; quantitative Lu-177 SPECT acquisitions of the abdomen 24 (+CT), 48, and 72 h p.i.; and a Lu-177
whole-body planar acquisition at 24 h post-therapy. Patient-specific 3D volumes of interest were segmented from the Ga-
68-PSMA-11 PET/CT, filled with activity information from the Lu-177 data, and imported into the FLUKA MC code
together with the patient CT. MC simulations of the BM absorbed dose were performed assuming a physiological BM
distribution according to the ICRP 110 reference male (MC1) or a displacement of active BM from the direct location of
bone lesions (MC2). Results were compared with those from S values (SMIRD). BM absorbed doses were correlated with
the decrease of lymphocytes, total white blood cells, hemoglobin level, and platelets. For two patients, an additional pre-
therapeutic Tc-99m-anti-granulocyte antibody SPECT/CT was performed for BM localization.
Results: Median BM absorbed doses were 130, 37, and 11mGy/GBq for MC1, MC2, and SMIRD, respectively. Significant
strong correlation with the decrease of platelet counts was found, with highest correlation for MC2 (MC1: r = − 0.63,
p = 0.04; MC2: r = − 0.71, p = 0.01; SMIRD: r = − 0.62, p = 0.04). For both investigated patients, BM localization via Tc-99m-
anti-granulocyte antibody SPECT/CT indicated a displacement of active BM from the direct location of lesions similar to
model MC2 and led to a reduction in the BM absorbed dose of 40 and 41% compared to MC1.
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Conclusion: Higher BM absorbed doses were observed for MC-based models; however, for MC2, all absorbed doses
were still below 2 Gy. MC1 resulted in critical values for some patients, but is suspected to yield strongly exaggerated
absorbed doses by neglecting bone marrow displacement. Image-based BM localization might be beneficial, and
future studies are recommended to support an improvement for the prediction of hematoxicities.
Keywords: Radioligand therapy, Dosimetry, Monte Carlo, Bone marrow, mCRPC, Lutetium, PSMA, Tc-99m-anti-
granulocyte antibody scintigraphy, Bone marrow localizationIntroduction
In radioligand therapy, dosimetry is recommended for
appropriate treatment planning and aims for maximizing
the absorbed dose to malignant structures, while minim-
izing the absorbed dose to risk organs. A variety of strat-
egies for the assessment of tissue absorbed doses exist,
which can be distinguished depending on how detailed
the patient-specific information is considered or depend-
ing on whether a 3D-absorbed dose model is used or
absorbed dose factors (S values) are applied [1–5].
Monte Carlo techniques can be used to fully simulate all
interactions of radioactive decay particles within the sur-
rounding material in a step-by-step manner. Various
Monte Carlo codes such as FLUKA or GEANT4 were
extended to applications in nuclear medicine and are
capable to consider the patient-specific 3D activity and
anatomical characteristics via inclusion of the SPECT,
PET, and CT data into the simulation [6–12]. Thus, 3D-
absorbed dose distributions with resolution and accuracy
depending on the input image data can be provided.
However, the absorbed dose to risk organs or tumors
during radioligand therapy is usually calculated via
organ-level S values, which were pre-calculated based on
standardized anthropomorphic phantoms and which
estimate the mean absorbed dose to the whole target
region based on the mean time-integrated activity in a
specified source region.
The active bone marrow (BM) is a main organ at risk
during Lu-177-PSMA ligand therapy, especially as
patients with advanced mCRPC often present with a high
bone tumor burden and a potentially reduced
hematological function [13–15]. Typically, bone marrow
dosimetry is performed by applying the aforementioned S
values and accounts for the self-absorbed dose to the bone
marrow from the blood, the cross-absorbed dose from the
remainder of the body (ROB), and the cross-absorbed
dose from major organs and tumors as specific source re-
gions [15–19]. However, during bone marrow dosimetry
using organ-level S values, simplifying assumptions have
to be made to estimate the absorbed dose from the overall
tumor distribution, as no pre-calculated S values exist that
consider all lesions in their size, shape, number, and
location. Thus, Monte Carlo simulations may lead toimproved bone marrow absorbed dose estimates, as they
have the potential to fully account for the patient-specific
3D disease characteristics.
Another limitation of classical bone marrow dosimetry
is that the actual localization of the active bone marrow
is a priori unknown. Bone lesions might lead to a dis-
placement of active bone marrow from the direct site of
metastases and thus activity accumulation, which would
drastically reduce the absorbed dose to the active bone
marrow [20, 21]. However, bone marrow dosimetry
using pre-calculated organ-level S values assumes a
physiological bone marrow distribution [16]. Clinical im-
aging methods, such as magnetic resonance imaging or
Tc-99m-anti-granulocyte antibody scintigraphy, can be
used for non-invasive active bone marrow localization,
within the spatial resolution of the corresponding
imaging modality [22–25]. Thus, such techniques might
overcome the limitation of an a priori unknown target
region for bone marrow dosimetry.
In this study, we performed 3D simulations of the
bone marrow absorbed dose for mCRPC patients, as-
suming either an active bone marrow distribution, which
is not altered by the bone tumor load, or a displacement
of active bone marrow from the location of bone metas-
tasis. These results were compared to the respective
bone marrow absorbed dose estimates derived via
organ-level S values. Subsequently, all absorbed dose es-
timates were further correlated with the patient-specific
changes in hematological parameters. For a subgroup of
investigated patients, a Tc-99m-anti-granulocycte anti-
body SPECT/CT was acquired prior to therapy, which
was further analyzed to investigate Monte-Carlo-based
bone marrow dosimetry with and without knowledge of
the patient-specific active bone marrow distribution.
If not indicated otherwise, the term bone marrow
always refers to the active bone marrow, which repre-
sents the radio-sensitive part of the overall bone marrow
mixture.
Material and methods
Patients and data acquisition
This study is based on the first cycle of 10 patients, who
showed PSMA avid soft tissue and bone lesions on the
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Patients P1–P4 were treated with on average 3.7 GBq
Lu-177-PSMA-617, while for all other patients, the dos-
ing scheme was increased to 6 GBq, according to initial
dosimetry results at our institution [15, 26] (Table 1).
Patient P7 received a fifth therapy cycle at our institu-
tion with prior image-based active bone marrow
localization and was included as patient P8 (Table 1), as
this rare data allows for an exemplarily comparison of
patient-specific bone marrow dosimetry without and
with knowledge of the patient-specific bone marrow
distribution. All patients received a 15-min abdominal
Lu-177 SPECT/CT scan and a 20-min whole-body pla-
nar scintigraphy at 24 h p.i., as well as a 15-min abdom-
inal SPECT at 48 h and 72 h p.i. on a dual-headed
Symbia T2 SPECT/CT (Siemens Medical Solutions,
Erlangen, Germany). The SPECT and planar whole-body
acquisitions were based on a standard Lu-177 imaging
protocol, using a medium-energy low-penetration colli-
mator, the photopeak at 208 keV (width 15%), and two
additional scatter windows at 170 keV (width 15%) and
240 keV (width 10%) [15, 26, 27]. For dosimetry pur-
poses, five venous blood samples were drawn from eachTable 1 Characteristics of mCRPC patients included in this study
P1 P2 P3 P4
Age 66 68 47 61
Activity (GBq) 3.7 3.7 3.7 3.7
Cycle 1 1 1 1
Metastases (VIS = visceral,
LYM = lymph, OSS = osseous)
OSS Mainly VIS
(liver), OSS,
LYM
Mainly
OSS, LYM
Mai
OSS
Initial TNM classification and
Gleason score
pT4, N1,
R1, G3,
Gleason 8
pT3b, pN1,
R0, G3,
Gleason 9
pT3a,
pN1, pR1,
Gleason 9
pT3
pN1
Gle
9
PSA (ng/ml) prior to RLT 1201 368 408 543
Pre-therapies (1, yes/0, no)
▪ Surgery 1 0 1 1
▪ Radiotherapy 1 1 0 1
▪ Anti-hormonal therapy
(including 2nd line anti-hormonal
therapy with bicalutamide,
enzalutamide, abiraterone acetate)
1 1 1 1
▪ Ra-223 1 0 1 0
▪ Chemotherapy
(docetaxel, cabazitaxel)
1 1 1 1
Blood baseline
▪ Leukocytes (G/l) 7.2 4.9 6 5.6
▪ Lymphocytes (G/l0 0.57 0.96 1.71 0.49
▪ Hemoglobin (g/dl) 14.1 12.3 12.8 9.6
▪ Thrombocytes (G/l) 195 307 323 291
▪ Erythrocytes (T/l) 4.79 4.31 4.36 4.08patient 30 and at maximum 80min post-start of infu-
sion, and before each image acquisition. Blood parame-
ters were further monitored as a part of clinical routine
until the next therapy cycle [28]. Monitoring of blood
element counts was performed at the morning prior to
therapy (baseline), each morning during the following 3
days until discharge, and at 4 and 8 weeks until the next
therapy cycle.
For patients P8 and P9, an additional Tc-99m-anti-
granulocyte antibody SPECT/CT (Scintimun, GLYCO-
TOPE Biotechnology GmbH, Heidelberg, Germany) was
acquired prior to radioligand therapy for localization of
the active bone marrow. A 25-min two-bed SPECT/CT
scan of thorax and abdomen was performed at 3–4 h
after the injection of approximately 400MBq. Image
acquisition followed a standard Tc-99m protocol using a
low-energy high-resolution collimator, a photopeak win-
dow of 140 keV (width 15%), and an additional scatter
window at 115 keV (width 20%).
All patients gave written consent to undergo radioli-
gand therapy. The study protocol was approved by the
local ethics committee of the Medical Faculty of the
Ludwig-Maximilians-University Munich, which waivedP5 P6 P7 P8 P9 P10 P11
73 63 82 83 79 67 88
6.0 6.0 6.0 6.0 6.0 6.1 6.1
1 1 1 5 1 1 1
nly
, LYM
Mainly
OSS,
LYM
OSS,
LYM
Mainly
OSS, LYM,
VIS
Mainly
OSS, LYM,
VIS
Mainly
OSS,
LYM
Mainly
OSS,
LYM
OSS
b,
, R1,
ason
pT3b,
pN1
T3a,
N1
pT4, pN1,
R1, G3,
Gleason 9
pT4, pN1,
R1, G3,
Gleason 9
n.a. pT3,
pN0, R1,
Gleason
7
n.a.
6 2311 0.86 65.7 65.6 418 20.6 52.1
1 1 1 1 1 1 0
1 0 1 1 0 1 0
1 1 1 1 1 1 1
0 0 0 0 0 1 0
1 1 0 0 1 1 0
5.2 4.54 5.41 4.85 5.31 2.73 7.84
0.56 1.14 0.95 0.48 0.94 0.28 2.06
10.9 13.3 10.5 8.4 10.5 8.3 12.1
235 227 450 305 223 89 281
3.86 4.11 3.96 3.25 3.55 3.2 3.64
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study is based on retrospective and irreversibly anon-
ymized patient data.Image reconstruction and quantification
Quantitative SPECT reconstruction was performed with
an in-house maximum-a-posteriori reconstruction algo-
rithm, which considers the correction for photon attenu-
ation based on the co-registered low dose attenuation
correction CT (AC-CT) (PMOD Version 3.609 rigid-
body co-registration), correction for photon scattering
based on the triple-energy-window (TEW) or dual-
energy-window (DEW) method, and compensation of
distance-dependent detector resolution using a Gaussian
detector response model. Final quantification was real-
ized by applying a system-specific calibration factor,
which was determined from an identically imaged and
reconstructed cylinder phantom of homogeneous and
known activity concentration [15, 27, 29].
Quantitative reconstruction of Ga-68-PSMA-11 PET/
CT scans was conducted as part of clinical routine using
the TrueX algorithm with 3 iterations, 21 subsets, and a
3D post-reconstruction Gaussian filter with a full-width
half maximum of 2 mm. The voxel volume in the PET
data was 4.1 × 4.1 × 5.0 mm3.
All Lu-177 planar whole-body images were corrected
for photon attenuation and scattering pixel by pixel via
an in-house MATLAB routine. Correction of photon at-
tenuation was achieved via a patient-specific μ-map,
which was generated from the whole-body CT of the
pre-therapeutic Ga-68-PSMA-11 PET/CT acquisition,
while the correction of photon scattering employed the
TEW method. A patient-specific calibration factor was
determined utilizing a cross-calibration with the corre-
sponding quantitative SPECT at 24 h post-injection [28].Reference bone marrow dosimetry using mass-scaled
organ-level S values
Bone marrow dosimetry utilizing phantom-based organ-
level S values was selected as reference method in this work.
It considered the blood, both kidneys, and the remainder of
body (ROB) as specific source regions [15–19, 28]. The re-
spective S values of the RADAR standardized male an-
thropomorphic phantom were used [30]. All S values were
scaled to the patient-specific anatomical conditions. The
time-integrated activities for the blood and both kidneys
were determined based on a bi-exponential and a mono-
exponential fit to the available time-activity measurements,
respectively. For determination of the blood-to-bone mar-
row absorbed dose, we employed a hematocrit-based red
marrow-to-blood activity concentration ratio (RMBLR), as
we assume no specific binding to bone marrow or blood
cells [16, 28, 31]. This assumption results in a reducedRMBLR compared to a RMBLR of one, which is typically
employed for Lu-177 PRRT.
The derivation of the time-integrated activity of the
ROB from a single planar whole-body scan was achieved
by applying a suitable hybrid SPECT-planar model,
which has been investigated in a previous study [28].
Briefly, a mono-exponential curve was fitted to the total
SPECT activity over time, and this curve was scaled with
the whole-body activity at 24 h p.i. afterwards to
estimate the patient-specific whole-body time-activity
curve. After integration over time, kidney and blood
time-integrated activities were subtracted to obtain the
number of decays within the ROB compartment [16]. As
the patient-specific lesion distribution was highly
variable for the patients investigated in this study, no
pre-calculated S values were available, which consider all
lesions in their size, shape, number, and location. Thus,
the consideration of the metastases and their non-
negligible activity uptake within the S value method was
achieved by including the total lesion activity within the
ROB compartment.
In a previous study, the contribution from the ROB in-
cluding the lesion activities was found to be the domin-
ating component of the total bone marrow absorbed
dose [28]. However, the patient-specific lesion distribu-
tion is assumed to be only inadequately considered via
classical S value dosimetry. To investigate differences be-
tween Monte-Carlo-based and classical S value bone
marrow dosimetry, all bone marrow absorbed doses
were correlated to the total bone lesion load, the time-
integrated tumor uptake, and the time-integrated ROB
retention (MATLAB Pearson’s correlation). The total
bone lesion load was obtained from the pre-therapeutic
Ga-68-PSMA-11 PET via PMOD kmeans segmentation
(PMOD Version 3.609), while time-integrated tumor up-
take and ROB retention were derived by integrating both
the mono-exponential ROB and lesion time-activity
curves. To obtain a total-body lesion time-activity curve
from the sequential abdominal SPECT, the assumption
that the kinetics of all abdominal lesions is equivalent to
that of all lesions throughout the patient body was made.
The total-body lesion time-activity curve was then derived
from all segmented tumors within the abdominal
sequential SPECT (kmeans segmentation, PMOD
Version 3.609), scaled with the ratio of total-to-abdominal
lesion load.Monte Carlo simulation of bone marrow absorbed dose
For each patient, the absorbed dose to the bone marrow
was simulated using the FLUKA MC code, which has been
extended and validated for applications in nuclear medi-
cine, and which is capable to include the patient-specific
3D anatomical and activity imaging data [6, 11, 12, 32].
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The pre-therapeutic diagnostic CT from the Ga-68-
PSMA-11 PET/CT scan served as patient-specific
whole-body anatomical map during the Monte Carlo
simulations. Therefore, the CT was converted to a
voxel-wise map of density and anatomical composition
as described by Botta et al. and as required by the MC
code [6]. The patient-specific and time-dependent 3D
whole-body Lu-177 activity distribution was described
by combining the information contained in the sequen-
tial Lu-177 SPECT, the Lu-177 whole-body planar scin-
tigraphy, and the whole-body PET/CT data. First, a
patient-specific 3D whole-body volume of interest (VOI)
map was generated by segmenting the kidneys, the tu-
mors, and the ROB in the PET/CT volume. Using the
sequential Lu-177 SPECT and the single Lu-177 whole-
body planar scintigraphy, the activity in these compart-
ments was assessed for each time point 24, 48, and 72 h
post-injection. Therefore, kidney VOIs and the overall
tumor load were semi-automatically segmented (kmeans
segmentation, PMOD Version 3.609) from both the
quantitative SPECT scan 24 h p.i. and the Ga-68-PSMA-
11 PET. The segmented kidney VOIs were confirmed by
visual comparison with the AC-CT and the diagnostic
CT, respectively. Both, the 24-h-based SPECT kidney
and tumor VOIs were then manually registered to the
following imaging days 48 h and 72 h post-
administration. The time-integrated activity per voxel
was determined for both compartments, to directly as-
sign a total number of decays per voxel to each VOI of
the patient-specific activity template. Thereby, the ab-
dominal lesion time-integrated activity was multiplied
with the ratio of total-to-abdominal lesion volume to es-
timate the total lesion time-integrated activity from the
sequential abdominal SPECT, as already described. The
ROB time-integrated activity was defined via the men-
tioned hybrid SPECT-planar model [28], while the ROB
VOI itself was derived from a VOI outlining the whole
CT volume from the PET/CT data.
Absorbed dose to the bone marrow
For most of the skeletal sites, the bone marrow shows a
heterogeneous microstructure composed of small mar-
row cavities containing a composition of active bone
marrow (BM) and inactive bone marrow (iaBM), with
these cavities being separated by the spongiosa, i.e.,
small ridges of hard bone (HB). This highly heteroge-
neous microstructure is not visible on routine clinical
imaging modalities. Thus, for simulation and estimation
of the bone marrow absorbed dose, we implemented a
weighting factor-based model into the FLUKA code,
similar to the two-factor mass-energy absorption coeffi-
cient method described by Lee et al. [33]. It estimates
the absorbed dose to the active bone marrow from theabsorbed dose simulated within the total bone mixture,
multiplied via a weighting factor w, which describes an
effective interaction probability within the active bone
marrow. This weighting factor can be calculated from the
particle energy E of the dose-depositing photons or elec-
trons; the fractions of active bone marrow, inactive bone
marrow, and hard bone (fBM, fiaBM, and fHB, respectively)
present in the skeletal region of interest; the photon mass
attenuation coefficients (μρ) or the electron mass stopping
powers (Sρ) of the skeletal constituents:
DBM ¼ Dbone  w; ð1:1Þ
w ¼
μBM Eð Þ
ρBM
μbone Eð Þ
ρbone
or w ¼
SBM Eð Þ
ρBM
Sbone Eð Þ
ρbone
; ð1:2Þ
μbone Eð Þ ¼ f BM 
μBM
ρBM
þ f iaBM 
μiaBM Eð Þ
ρiaBM
þ f HB 
μHB Eð Þ
ρHB
 or
Sbone Eð Þ ¼ f BM 
SBM Eð Þ
ρBM
þ f iaBM 
SiaBM Eð Þ
ρiaBM
þ f HB 
SHB Eð Þ
ρHB
;
ð1:3Þ
f BM ¼
mBM
mbone
and in general f i
¼ mi
mbone
; i∈ BM; iaBM;HBf g; ð1:4Þ
f BM þ f iaBM þ f HB ¼ 1: ð1:5Þ
fBM, fiaBM, and fHB reference values were available for
13 active-marrow-bearing bone regions according to the
ICRP 110 reference male [34]. For each patient, these 13
bone regions were segmented onto the patient-specific
diagnostic CT from the Ga-68-PSMA-11 PET/CT, and
the aforementioned reference fractions fBM, fiaBM, and
fHB were assigned to each voxel according to its region
affiliation. To facilitate segmentation of these 13 regions
for each patient, a bone region template was employed.
Therefore, the whole skeleton of 5 patients was
segmented via a HU threshold of 200 on the diagnostic
CT from the Ga-68-PSMA-11 PET/CT, and the
remaining holes in these skeletal VOIs were manually
filled afterwards (PMOD Version 3.609). For template
generation, the segmented bone VOIs from all five pa-
tients were co-registered onto each other using PMOD
non-rigid co-registration. Finally, all 13 regions were
manually segmented on this template. For each patient,
the whole skeleton was segmented in the same manner
as for template generation, and the region-specific tem-
plate was non-rigidly co-registered onto each patient-
specific skeletal VOI, to automatically define both the
patient-specific bone region classification and the related
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values fBM (Fig. 1).
This pre-defined active bone marrow distribution was
used in two ways during Monte-Carlo-based bone mar-
row dosimetry. For model MC1, the active bone marrow
distribution remained unchanged, assuming a co-
localization of lesions and active bone marrow. For the
second model MC2, all previously segmented lesion-
containing voxels were removed from the active bone
marrow distribution, to simulate the effect of a complete
bone marrow displacement from the metastatic sites
onto the absorbed dose estimates.
As for SMIRD, absorbed dose estimates were corre-
lated to the bone lesion load, the time-integrated tumor
uptake, and the time-integrated ROB retention
(MATLAB Pearson’s correlation).
Simulation
During simulation, photon production, and transport
thresholds were set to 1 keV (mean range < 1mm for all
tissues [35]). The corresponding electron thresholds were
chosen as 10 keV (mean range < 0.01mm for all tissues).
109 decays were simulated for each simulation study.
Correlation with blood parameters
For the patients included in this study, all bone marrow
absorbed doses were correlated (MATLAB Pearson’s
correlation) with the change of hematological parame-
ters after the investigated therapy cycle (Table 1), i.e.,
the ratio of nadir-to-baseline values of platelet, lympho-
cyte, and leukocyte counts as well as of hemoglobin
level. Particularly, the goal was to assess for the overall
patient cohort whether patient-specific Monte-Carlo-
based bone marrow dosimetry results in improved cor-
relation with the hematological outcome compared to
classical S value dosimetry.
Comparison of bone marrow absorbed doses
Bone marrow dosimetry estimates derived from the bone
marrow models MC1, MC2, and SMIRD were compared
among each other, and respective differences were
further correlated with the bone lesion load, the time-Fig. 1 Exemplary workflow for definition of skeletal compositions. a Exemp
bone VOI. c Automatic definition of bone regions from non-rigidly co-regisintegrated tumor uptake, and the time-integrated ROB
retention (MATLAB Pearson’s correlation), to estimate
which influencing factors of absorbed dose modeling
define differences between the investigated models.
Bone marrow dosimetry using Tc-99m-anti-granulocyte
antibody scintigraphy
Pre-therapeutic Ga-68-PSMA-11 PET and Tc-99m-anti-
granulocyte antibody SPECT distributions were visually
compared with respect to the overlap between tumor up-
take and the accumulation in the Tc-99m-anti-granulo-
cyte antibody scintigraphy. In a second step, the Tc-99m-
anti-granulocyte antibody SPECT/CT was non-rigidly co-
registered to the Ga-68-PSMA-11 PET/CT data (PMOD
Version 3.609) and considered during the Monte Carlo
absorbed dose calculation as active bone marrow VOI
(gMC3). Respective absorbed dose estimates were com-
pared with those from model MC1 for no bone marrow
displacement from the direct location of metastasis, MC2
assuming full bone marrow displacement, and SMIRD.
Results
Reference bone marrow dosimetry using mass-scaled
organ-level S values
Median bone marrow absorbed dose estimates as derived
via S values (SMIRD) were found to be 11mGy/GBq (6–
25mGy/GBq) (Table 2). Individual bone marrow
absorbed doses showed a weak positive correlation with
the bone lesion load (r = 0.36, p = 0.27, R2 = 0.13). A strong
positive correlation with the time-integrated ROB reten-
tion (r = 0.87, p < 0.01, R2 = 0.74) and with the time-
integrated tumor uptake (r = 0.88, p < 0.01, R2 = 0.75) was
found.
Analysis of blood parameters revealed a weak negative
correlation of bone marrow absorbed dose estimates
with the change of hemoglobin level (r = − 0.19, p = 0.60,
R2 = 0.04). A moderate negative correlation was found
for the change of lymphocyte counts (r = − 0.49, p = 0.15,
R2=0.24) and total white blood cells (r = − 0.45, p = 0.20,
R2=0.20), while the change of platelet counts showed a
strong negative correlation (r = − 0.62, p = 0.04, R2 =
0.38) (Fig. 2).lary patient CT. b Semi-automatic segmentation of patient-specific
tered template
Table 2 Bone marrow absorbed dose estimates as derived either using S values (SMIRD), Monte Carlo simulations under the
assumption of a physiological active bone marrow distribution (MC1), or Monte Carlo simulations assuming no active bone marrow
at the direct location of the bone lesions (MC2)
Patient (administered
activity in GBq)
SMIRD
(mGy)
MC1
(mGy)
MC2
(mGy)
Bone lesion
load (ml)
Time-integrated tumor
uptake (GBq × s/ml)
Time-integrated ROB
retention (GBq × s/ml)
P1 (3.7) 30 493 81 402 141 3
P2 (3.7) 41 109 109 33 87 4
P3 (3.7) 52 274 137 448 59 5
P4 (3.7) 63 3192 281 1123 609 4
P5 (6.0) 120 2139 515 1124 523 17
P6 (6.0) 36 22 22 50 91 6
P7 (6.0) 150 5595 635 727 1130 26
P8 (6.0) 46 1123 225 1298 159 10
P9 (6.0) 40 684 202 836 128 9
P10 (6.1) 66 782 347 1383 84 17
P11 (6.1) 36 403 206 467 64 9
Additionally, bone lesion load, time-integrated tumor uptake, and ROB retention are provided for each patient
Fig. 2 Results for the correlation analysis between the investigated models for bone marrow absorbed dose calculation and the change of blood
element counts (from left to right: MC1, MC2, and SMIRD). Coefficients of the correlation model (a × x + b) were indicated, in combination with
the 95% confidence bounds (brackets)
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Under the assumption of an unaltered and physiological
active bone marrow distribution (MC1), median
absorbed dose estimates were found to be 130 mGy/GBq
(4–933 mGy/GBq) (Table 2). Further, for model MC1, a
weak positive correlation with the bone lesion volume
(r = 0.38, p = 0.24, R2 = 0.15), while a strong up to very
strong positive correlation with the time-integrated ROB
retention (r = 0.71, p = 0.01, R2 = 0.50) and time-
integrated tumor uptake (r = 0.98, p < 0.01, R2 = 0.97)
was observed. Analysis of blood parameters revealed a
weak negative correlation with the change of lymphocyte
counts (r = − 0.23, p = 0.52, R2 = 0.05), total white blood
cells (r = − 0.18, p = 0.61, R2 = 0.03), and hemoglobin
level (r = − 0.39, p = 0.26, R2 = 0.15). A strong negative
correlation for the change of platelet counts (r = − 0.63,
p = 0.04, R2 = 0.38) was found (Fig. 2).
For model MC2, which assumes a full displacement of
active bone marrow from the direct location of each le-
sion, median bone marrow absorbed dose estimates were
37mGy/GBq (4–106 mGy/GBq) (Table 2). For MC2, a
moderate positive correlation with the bone lesion volume
was found (r = 0.58, p = 0.06, R2 = 0.33), while a strong up
to very strong positive correlation with the time-integrated
tumor uptake and ROB retention was observed (r = 0.82,
p < 0.01, R2 = 0.68 and r = 0.92, p < 0.01, R2 = 0.84). Con-
cerning the blood parameters, a weak negative correlation
was found for the change of hemoglobin level (r = − 0.20,Fig. 3 Exemplary Monte Carlo simulation results for patients 3, 4, 8, and 9.
row: MIP for simulated absorbed dose within the bone marrowp = 0.59, R2 = 0.04) and total white blood cells (r = − 0.27,
p = 0.44, R2 = 0.08), while lymphocyte counts (r = − 0.52,
p = 0.13, R2 = 0.27) showed a moderate negative correlation.
Analysis of the change of platelet counts showed a strong
negative correlation (r = − 0.71, p = 0.01, R2 = 0.50) (Fig. 2).
Exemplary simulation results are provided in Fig. 3 for
patients 3, 4, 8, and 9. Patients 4 and 8 present with a
comparable bone lesion load; however, a clearly higher
bone marrow absorbed dose was observed for patient 4
and particularly MC1, due to a fourfold higher time-
integrated tumor uptake (Table 2).
Comparison of bone marrow absorbed doses
The median ratio between models MC1 and SMIRD was
a factor of 17 (1–50) (Table 3). The highest differences
were observed for patients 4, 7, and 8, who showed a
combination of a comparatively high bone lesion vol-
ume, a high time-integrated tumor uptake, and a high
ratio of time-integrated tumor uptake to ROB retention
(Table 3). The lowest differences were found for patients
2, 3, and 6. Patients 2 and 6 showed the lowest bone
lesion volume (< 50ml), while for patient 3 both a
comparatively low tumor uptake and ROB retention
were observed (Table 3). In general, the differences
between MC1 and SMIRD were mainly driven by the
time-integrated tumor uptake and the bone lesion
volume, respectively (r = 0.77, p < 0.01, R2 = 0.59, and r =
0.60, p = 0.05, R2 = 0.36).Upper row: MIP from pre-therapeutic Ga-68- PSMA-11 PET/CT; lower
Table 3 Ratio of bone marrow absorbed dose estimates based
on Monte Carlo simulations and S values
Patient MC1/SMIRD MC2/SMIRD MC1/MC2
P1 17 3 6
P2 3 3 1
P3 5 3 2
P4 50 4 11
P5 18 4 4
P6 1 1 1
P7 37 4 9
P8 27 5 5
P9 17 5 3
P10 12 5 2
P11 11 6 2
Median 17 4 3
Gosewisch et al. EJNMMI Research            (2019) 9:76 Page 9 of 14The comparison between model MC2 and SMIRD re-
vealed a median ratio of 4 (1–6) (Table 3). The lowest
difference was obtained again for patient 6, while all
other patients showed a similar deviation by a factor of 3
to 6, whereupon the differences between MC2 and
SMIRD mainly show a strong positive correlation with
the bone lesion volume (r = 0.63, p = 0.04, R2 = 0.40).
The median ratio of MC1 to MC2 was found to be 3 (1–
11), with the highest differences being found for patients 4
and 7, which both show the highest time-integrated tumor
uptake (Table 3). In addition, a strong positive correlation
between the ratios MC1 to MC2 with the time-integrated
tumor uptake was found (r = 0.78, p < 0.01,R2 = 0.61).
Bone marrow dosimetry using Tc-99m-anti-granulocyte
antibody scintigraphy
For patients 8 and 9, bone marrow absorbed dose esti-
mates were re-analyzed using the Tc-99m-anti-granulo-
cyte-based active bone marrow VOI (gMC3). For patient
8, MC1 and MC2 revealed a bone marrow absorbed
dose of 1223 and 225 mGy, respectively, compared to 46
mGy for SMIRD. For the Tc-99m-anti-granulocyte-
based VOI, an absorbed dose of 718 mGy was found, i.e.,
a reduction of approximately 41% compared to MC1.
The ratio of model gMC3 compared to MC2 and
SMIRD was found to be 3 and 17, respectively (Table 4).
For patient 9, absorbed dose estimates for MC1, MC2,
and SMIRD were found to be 684, 202, and 40mGy, re-
spectively. Applying the Tc-99m-anti-granulocyte-basedTable 4 Comparison of bone marrow absorbed dose estimates base
Patient MC1 (mGy) MC2 (mGy)
P8 1123 225
P9 684 202
gMC3 uses the patient-specific Tc-99m-anti-granulocyte-based active bone marrow
assumes a physiological distribution, however with displacement of active bone maVOI yielded a bone marrow absorbed dose of 408 mGy.
Thus, compared to MC1, the bone marrow absorbed
dose decreased by 40%, while gMC3 produced two- and
tenfold higher absorbed dose estimates compared to
MC2 and SMIRD (Table 4).
Furthermore, visual interpretation of Ga-68-PSMA-11
PET and Tc-99m-anti-granulocyte antibody scintigraphy
indicates a low overlap between accumulation patterns
and a displacement of active bone marrow from meta-
static lesions for both investigated patients (Figs. 4 and 5).Discussion
The bone marrow is potentially the most critical organ
and most limiting factor of the therapeutic window
during Lu-177-PSMA therapy of mCRPC patients, as
those patients are usually heavily pre-treated and often
present with a considerable bone lesion load [14]. In a
study of Rahbar et al. with 145 patients and an average
administered activity of 5.9 GBq per cycle, hematoxicity
showed the highest incidence for all grades as well as for
grade 3–4 events [36]. Thus, bone marrow dosimetry is
highly recommended in those patients. However, for
bone marrow dosimetry to become predictive for hema-
toxicity, all relevant patient-specific parameters must be
considered. These include the patient-specific activity
accumulation over time, the anatomical characteristics,
an appropriate localization of the bone marrow target
region, and, not least, pre-therapies and the patient-
specific disease and hematological baseline status.
This study focuses on three relevant issues: First, we
developed an approach for Monte-Carlo-based absorbed
dose calculations, which can fully consider the patient-
specific 3D activity and anatomical characteristics in
contrast to the classical S value dosimetry. Second, we
compared the effect of different models for active bone
marrow localization during Monte-Carlo-based bone
marrow dosimetry. The latter aspect is especially linked
to the question whether patient-specific active bone
marrow localization, e.g., via Tc-99m-anti-granulocyte
scintigraphy, might be beneficial to avoid bone marrow
toxicity. Third, we investigated whether for the patient
cohort under study, Monte-Carlo-based absorbed dose
calculation shows an improved correlation with the
change of hematological parameters, and whether fully
patient-specific bone marrow dosimetry can potentially
provide an improved prediction for hematoxicities.d on Monte Carlo simulations for patients 8 and 9
gMC3 (mGy) SMIRD (mGy)
718 46
408 40
VOI. MC1 assumes a physiological active bone marrow distribution, while MC2
rrow from the direct site of metastases
Fig. 4 Results from Tc-99m-anti-granulocyte antibody SPECT/CT (b) in comparison to the Ga-68-PSMA-11 PET/CT (a) for patient 8
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study is low, our preliminary results already indicate a large
range between bone marrow absorbed dose estimates for
Monte Carlo and S value calculations. The model-specific
correlation of bone marrow absorbed dose estimates with
segmented bone lesion volume, time-integrated tumor up-
take, and ROB retention, as performed during this study,
supports that multiple patient-specific factors should be
taken into consideration to reduce the uncertainty of bone
marrow dosimetry. SMIRD-based bone marrow dosimetry
mainly accounts for the time-integrated ROB and lesion
uptake characteristics; however, respective absorbed dosesFig. 5 Results from Tc-99m-anti-granulocyte antibody SPECT/CT (b) in comrevealed only a weak correlation with the patient-specific
and highly heterogeneous 3D bone lesion distribution. For
MC2-based absorbed dose estimates, a strong and signifi-
cant correlation with tumor uptake, ROB retention, and
bone lesion volume was found, while bone marrow
absorbed dose calculations during model MC1 are clearly
dominated by the time-integrated tumor uptake. Results
from correlation analysis support that also for 3D-based
absorbed dose calculation, the total bone lesion volume is
not the only influencing factor of the bone marrow
absorbed dose, and risk patients should be stratified accord-
ing to multiple parameters.parison to the Ga-68- PSMA-11 PET/CT (a) for patient 9
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Monte-Carlo-based calculations resulted in higher bone
marrow absorbed doses than the classical S value ap-
proach. For both models, MC2 and SMIRD, bone mar-
row absorbed dose estimates were well below the
typically applied threshold of 2 Gy [19]. Although for
MC2 the absorbed dose estimates were on median four-
fold higher than those achieved with the reference model
SMIRD, the deduction that multiple therapy cycles are
applicable for these patients without the risk of severe
marrow toxicities seems reasonable, at least with regard
to the current dose limit. However, the assumption of
full displacement of active bone marrow, as included in
model MC2, might not be a priori justified in each pa-
tient and might lead to an underestimation of the bone
marrow absorbed dose. For model MC1, assuming a
physiological and unaltered active bone marrow distribu-
tion, median absorbed doses of 130 mGy/GBq were
found with on median 17-fold and 3-fold higher
absorbed dose estimates compared to SMIRD and MC2,
respectively. According to dosimetry using model MC1,
patients 4, 5, 7, and 8 would have received a bone mar-
row absorbed dose close to or in some cases even
strongly exceeding the 2 Gy limit, with the consequent
risk for severe marrow toxicities in these patients.
However, none of the patients presented severe marrow
damage, even after multiple therapy cycles. This obser-
vation questions the general applicability and signifi-
cance of models like MC1, which do not account for
bone marrow displacement by tumor lesions, especially
in the presence of a heavy skeletal tumor burden.
Visual analysis of Tc-99m-anti-granulocyte antibody
SPECT scans supports this thesis, as it indicates a
displacement of active bone marrow from the direct lo-
cation of bone lesions for both exemplarily investigated
patients. In these patients, the re-analysis of bone
marrow absorbed dose estimates using the individual
Tc-99m-anti-granulocyte-based active bone marrow
VOIs resulted in a clear absorbed dose reduction of
approximately 40% compared to MC1, although the
absorbed dose values were still higher than those from
MC2. However, both the Ga-68-PSMA-11 PET and the
Tc-99m-anti-granulocyte antibody SPECT have a finite
resolution, which intrinsically results in a certain artifi-
cial overlap of both activity distributions and thus in an
increased absorbed dose estimate compared to MC2.
Furthermore, co-registration between both modalities is
in general not perfect, particularly for challenging
regions such as the ribs or the sternum, which might
additionally cause a local overlap between tumor and
bone marrow accumulation. Both finite spatial reso-
lution and imperfect co-registration interfere with a po-
tential incomplete active bone marrow displacement.
Despite the additional complexity introduced by thefinite resolution of the involved imaging systems and by
the imperfect co-registration, the utilization of the add-
itional image data from the Tc-99m-anti-granulocyte
antibody scintigraphy may improve individualized bone
marrow dosimetry by providing a realistic upper limit
for the bone marrow absorbed dose. For patient 8, the
usage of a Tc-99m-anti-granulocyte-based VOI resulted
in a reduction of a total bone marrow absorbed dose
from 1.1 Gy (MC1) to an expected maximum dose of
0.7 Gy. It may be hypothesized that the typically applied
upper limit for the bone marrow absorbed dose of 2 Gy
is too high for patients with advanced cancer disease, ex-
tensive skeletal tumor burden, and potentially decreased
hematological function due to various pre-therapies.
Despite the relatively small additional bone marrow
absorbed dose (approx. 10 mSv for 400MBq), Tc-99m-
anti-granulocyte antibody scintigraphy might be justified
in such patients. Studies based on a larger patient cohort
are needed to identify, whether image-based active bone
marrow localization in combination with Monte-Carlo-
based absorbed dose calculation really improves the
correlation between bone marrow dosimetry and hema-
toxicities, and may therefore be suitable to guide therapy
planning in future workflows. Still, the comparison be-
tween models MC1 and MC2 demonstrates that the a
priori unknown patient-specific active bone marrow
distribution results in a large uncertainty of the bone
marrow absorbed doses, even if Monte Carlo techniques
are applied for absorbed dose modeling. Further, future
studies should be performed to find an appropriate
threshold for the bone marrow absorbed dose for Lu-
177-PSMA therapy [14].
The resolution of non-invasive active bone marrow
localization could be further improved by MRI bone
marrow localization, which would also be beneficial if
even small additional contributions to the bone marrow
absorbed dose must be avoided [24, 25]. However, in
clinical daily routine, the localization of active bone mar-
row in a large part of the patient body should be feasible
with acceptable measurement and processing time, and
it should be available for several patients per week.
Further, a reduction of processing complexity and effort
accompanied by a potential enhancement of the accur-
acy of the derived information is desirable. This could be
achieved, for instance, by employing a standardized
method for patient positioning over multiple scans at
the same or at different imaging modalities via patient-
adaptable storage matrasses, which facilitates image co-
registration [37].
To derive a patient-specific activity template from the
Ga-68-PSMA-11 PET instead from the Lu-177-SPECT
reduces issues of spatial resolution during absorbed dose
calculation. Further, for the patients considered in this
study, only SPECT acquisitions of the abdomen were
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distribution in the overall body is important. Using the
Ga-68-PSMA-11 PET to model the 3D activity accumu-
lation during therapy is an approximation and only ap-
plicable if the delay between PET acquisition and
therapy is small (on average 2.5 weeks in this study) and
if there is no change in the overall lesion load. To switch
to a fully Lu-177-based activity template, further investi-
gations are desired to improve the spatial resolution of
the Lu-177 imaging and to enable a fast whole-body Lu-
177-SPECT acquisition. Filling a fixed patient-specific
activity VOI template with the respective segmented
VOI activities from sequential Lu-177 imaging reduces
co-registration errors, which could otherwise lead to an
artificially increased bone marrow absorbed dose.
The analysis of blood parameters revealed a significant
(p < 0.05) and strong negative correlation only for the
change of platelet counts, irrespective of the exact bone
marrow model used. The highest correlation was ob-
tained with model MC2, which includes the assumption
of full displacement of active bone marrow from the dir-
ect site of the bone lesions. To exploit the potential and
impact of bone marrow dosimetry for therapy planning,
a more comprehensive investigation of the correlation of
the change of blood element counts with bone marrow
absorbed dose estimates is desired. For this purpose,
blood analysis should consider a higher number of pa-
tients and a prolonged time period. Both the baseline
hematological status and its course after therapy are
known to be affected by various parameters, such as pre-
therapies or total lesion volume [17, 38–40]. Thus, a pa-
tient stratification as for example proposed by Walrand
et al. is mandatory, if the correlation between bone mar-
row absorbed doses and hematological response to ther-
apy shall be analyzed [40]. So far, the correlation of bone
marrow absorbed doses and blood parameters for differ-
ent Lu-177-based radioligand therapies was assessed using
S value-based methods. Svensson et al. observed moderate
and significant correlations for the decrease of
hemoglobin level, total white blood cells, and platelet
counts for Lu-177 PRRT and for 46 investigated patients
[17]. By contrast, Forrer et al. found no correlation be-
tween the decrease of platelet counts and bone marrow
absorbed dose estimates for Lu-177 PRRT based on 15
patients and monitoring of hematological function until 6
weeks after treatment [18].
In clinical routine, the application of Monte Carlo
simulations for dose calculations may be too time-
consuming, especially if the simulation has to consider a
large part of the patient body and small voxels (e.g.,
0.05–0.001 ccm). However, Monte Carlo simulations can
be made feasible with computing clusters. In this way,
results with a high statistical validity could be obtained
in 1 day, which is acceptable with respect to the timegap between successive cycles of radioligand therapy. An
intermediate method for fast 3D dosimetry within mi-
nutes, which compromises the consideration of Monte
Carlo techniques and computational effectiveness, is the
application of Monte-Carlo-based dose kernels [41, 42].
Further investigations of this approach may be advisable
to prospectively facilitate improved clinical dosimetry for
monitoring and planning of radioligand therapies.
In this work, we introduced a weighting-based model
to represent the different compartments of active and in-
active bone marrow and hard bone. This model repre-
sents a reasonable simplification for the application to
clinical routine imaging data, which have a spatial reso-
lution above the characteristic size of the bone marrow
microstructure. Hybrid Monte-Carlo-based models that
alternate between macroscopic models of the overall pa-
tient anatomy and detailed microscopic models of the
skeletal system are time-consuming but might further
improve bone marrow absorbed dose estimates, at least
for the understanding of important mechanisms to
assess risk factors for marrow toxicities [34, 43].
Conclusion
Monte-Carlo-based bone marrow absorbed doses were
found to be significantly increased compared to those
derived from classical S value dosimetry. Particularly, a
large spread between Monte-Carlo-based and S value
bone marrow absorbed doses was observed, which im-
plies a large uncertainty, especially for S value dosimetry
due to the lack of an appropriate consideration of the
patient-specific highly heterogeneous 3D lesion distribu-
tion. However, even for Monte-Carlo-based bone mar-
row dosimetry, the a priori unknown patient-specific
active bone marrow distribution produces a large uncer-
tainty of bone marrow absorbed doses. Assuming a co-
localization between active bone marrow and all lesions
(MC1) is hypothesized to lead to too exaggerated
absorbed dose values (> 2 Gy per cycle for 27% of inves-
tigated cycles), as these values were not in concordance
with the observation of severe hematological toxicities.
Simultaneously, the a priori assumption of a full
displacement of active bone marrow for each patient
(MC2) might underestimate the patient-specific
absorbed dose. Patient-specific image-based active mar-
row localization, as performed for a small subgroup of
patients, yielded to intermediate bone marrow absorbed
doses compared to MC1 and MC2, although issues of
co-registration and finite image resolution might inter-
fere with incomplete active bone marrow displacement.
Future studies based on a larger patient cohort are rec-
ommended, to particularly determine whether patient-
specific active bone marrow localization in combination
with Monte-Carlo-based absorbed dose modeling can
improve the prediction of hematoxicities and thus
Gosewisch et al. EJNMMI Research            (2019) 9:76 Page 13 of 14enables to exploit the full therapeutic window of Lu-
177-PSMA therapy. Preliminary results showed a signifi-
cant and strong correlation between platelet decrease
and bone marrow absorbed doses, irrespective of the
exact dosimetry model; however, highest correlation was
observed for MC2.
Abbreviations
AC-CT: Low dose attenuation correction CT; BM: Bone marrow;
CT: Computed tomography; ICRP: Internal Commission on Radiological
Protection; MC: Monte Carlo; mCRPC: Metastasized castration-resistant
prostate cancer; MIRD: Medical Internal Radiation Dose (Committee);
PET: Positron emission tomography; PRRT: Peptide receptor radionuclide
therapy; PSMA: Prostate-specific membrane antigen; RADAR: Radiation Dose
Assessment Resource; ROB: Remainder of the body; SPECT: Single-photon
emission computed tomography; VOI: Volume of interest
Acknowledgements
Not applicable.
Authors’ contributions
AG, HI, AT, PB, SZ, and GB contributed to the concept and design of the
study. AG, HI, ST, JB, and LK carried out all the data analysis. AM and KP
provided the FLUKA MC code. FJG was responsible for the
radiopharmaceutical production. All authors contributed to the draft of the
manuscript. All authors read and approved the manuscript.
Funding
This work was partly funded by the German Research Foundation (DFG)
within the Research Training 381 Group GRK 2274.
Availability of data and materials
Please contact the corresponding author for data request.
Ethics approval and consent to participate
This study is based on retrospective and anonymized data, which was
acquired for routine clinical dosimetry (Ethics Committee of LMU Munich).
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Department of Nuclear Medicine, University Hospital, LMU Munich,
Marchioninistrasse 15, 81377 Munich, Germany. 2Heidelberg Ion Beam
Therapy Center, University Hospital Heidelberg, Heidelberg, Germany.
3Department of Medical Physics, Ludwig-Maximilians-Universität München,
Garching b. München, Germany.
Received: 14 May 2019 Accepted: 30 July 2019
References
1. Stabin M, Flux G. Internal dosimetry as a tool for radiation protection of the
patient in nuclear medicine. Biomedical Imaging and Intervention Journal.
2007;3(2):e28.
2. Ljungberg M, Sjögreen-Gleisner K. The accuracy of absorbed dose estimates
in tumours determined by quantitative SPECT: a Monte Carlo study. Acta
oncologica. 2011;50(6):981–9.
3. Grimes J, Celler A. Comparison of internal dose estimates obtained using
organ-level, voxel S value, and Monte Carlo techniques. Medical physics.
2014;41(9):092501.
4. Cremonesi M, et al. Dosimetry in peptide radionuclide receptor therapy: a
review. Journal of nuclear medicine. 2006;47(9):1467–75.
5. Bolch WE, et al. MIRD pamphlet no. 21: a generalized schema for
radiopharmaceutical dosimetry—standardization of nomenclature. Journal
of Nuclear Medicine. 2009;50(3):477–84.6. Botta F, et al. Use of the FLUKA Monte Carlo code for 3D patient-specific
dosimetry on PET-CT and SPECT-CT images. Physics in Medicine & Biology.
2013;58(22):8099.
7. Kost SD, et al. VIDA: a voxel-based dosimetry method for targeted
radionuclide therapy using Geant4. Cancer Biotherapy and
Radiopharmaceuticals. 2015;30(1):16–26.
8. Ljungberg M, et al. 3D absorbed dose calculations based on SPECT:
evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer
Biotherapy and Radiopharmaceuticals. 2003;18(1):99–107.
9. Ljungberg M, et al. A 3-dimensional absorbed dose calculation method based
on quantitative SPECT for radionuclide therapy: evaluation for 131I using
Monte Carlo simulation. Journal of Nuclear Medicine. 2002;43(8):1101–9.
10. Chiavassa S, et al. OEDIPE: a personalized dosimetric tool associating voxel-
based models with MCNPX. Cancer biotherapy & radiopharmaceuticals.
2005;20(3):325–32.
11. Fasso, A., et al, FLUKA: a multi-particle transport code. 2005, CERN-2005-10.
12. Böhlen T, et al. The FLUKA code: developments and challenges for high
energy and medical applications. Nuclear data sheets. 2014;120:211–4.
13. Baum RP, et al. Lutetium-177 PSMA radioligand therapy of metastatic
castration-resistant prostate cancer: safety and efficacy. Journal of Nuclear
Medicine. 2016. jnumed. 115.168443.
14. Kabasakal L, et al. Lu-177-PSMA-617 prostate-specific membrane antigen
inhibitor therapy in patients with castration-resistant prostate cancer:
stability, bio-distribution and dosimetry. Molecular imaging and radionuclide
therapy. 2017;26(2):62.
15. Delker A, et al. Dosimetry for 177 Lu-DKFZ-PSMA-617: a new
radiopharmaceutical for the treatment of metastatic prostate cancer.
European journal of nuclear medicine and molecular imaging. 2016;43(1):
42–51.
16. Hindorf C, et al. EANM Dosimetry Committee guidelines for bone marrow
and whole-body dosimetry. European journal of nuclear medicine and
molecular imaging. 2010;37(6):1238–50.
17. Svensson J, et al. A novel planar image-based method for bone marrow
dosimetry in 177 Lu-DOTATATE treatment correlates with haematological
toxicity. EJNMMI physics. 2016;3(1):21.
18. Forrer F, et al. Bone marrow dosimetry in peptide receptor radionuclide
therapy with [177 Lu-DOTA 0, Tyr 3] octreotate. European journal of nuclear
medicine and molecular imaging. 2009;36(7):1138.
19. Sandström M, et al. Individualized dosimetry of kidney and bone marrow in
patients undergoing 177Lu-DOTA-octreotate treatment. Journal of Nuclear
Medicine. 2013;54(1):33–41.
20. Logothetis CJ, Lin S-H. Osteoblasts in prostate cancer metastasis to bone.
Nature Reviews Cancer. 2005;5(1):21.
21. Morrissey C, Vessella RL. The role of tumor microenvironment in prostate
cancer bone metastasis. Journal of cellular biochemistry. 2007;101(4):873–86.
22. Agool A, et al. Radionuclide imaging of bone marrow disorders. European
journal of nuclear medicine and molecular imaging. 2011;38(1):166–78.
23. Berg BCV, et al. Magnetic resonance imaging of the normal bone marrow.
Skeletal radiology. 1998;27(9):471–83.
24. Moulopoulos LA, Dimopoulos MA. Magnetic resonance imaging of the
bone marrow in hematologic malignancies. Blood. 1997;90(6):2127–47.
25. Pichardo JC, Milner RJ, Bolch WE. MRI measurement of bone marrow cellularity
for radiation dosimetry. Journal of Nuclear Medicine. 2011;52(9):1482–9.
26. Fendler WP, et al. Preliminary experience with dosimetry, response and
patient reported outcome after 177Lu-PSMA-617 therapy for metastatic
castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581.
27. Ljungberg M, et al. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for
quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical
therapy. Journal of nuclear medicine. 2016;57(1):151–62.
28. Gosewisch A, et al. Patient-specific image-based bone marrow dosimetry in
Lu-177-[DOTA 0, Tyr 3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy:
investigation of a new hybrid image approach. EJNMMI research. 2018;8(1):76.
29. Dewaraja YK, et al. MIRD pamphlet no. 23: quantitative SPECT for patient-
specific 3-dimensional dosimetry in internal radionuclide therapy. Journal of
Nuclear Medicine. 2012;53(8):1310–25.
30. Stabin MG, et al. RADAR reference adult, pediatric, and pregnant female
phantom series for internal and external dosimetry. Journal of Nuclear
Medicine. 2012;53(11):1807–13.
31. Herrmann K, et al. Biodistribution and radiation dosimetry for a probe
targeting prostate-specific membrane antigen for imaging and therapy.
Journal of Nuclear Medicine. 2015;56(6):855–61.
Gosewisch et al. EJNMMI Research            (2019) 9:76 Page 14 of 1432. Parodi K, et al. Clinical CT-based calculations of dose and positron emitter
distributions in proton therapy using the FLUKA Monte Carlo code. Physics
in Medicine & Biology. 2007;52(12):3369.
33. Lee C, et al. An assessment of bone marrow and bone endosteum
dosimetry methods for photon sources. Physics in Medicine & Biology.
2006;51(21):5391.
34. Hough M, et al. An image-based skeletal dosimetry model for the ICRP
reference adult male—internal electron sources. Physics in Medicine &
Biology. 2011;56(8):2309.
35. https://www.nist.gov/pml/stopping-power-range-tables-electrons-protons-
and-helium-ions.
36. Rahbar K, et al. German multicenter study investigating 177Lu-PSMA-617
radioligand therapy in advanced prostate cancer patients. Journal of
Nuclear Medicine. 2017;58(1):85–90.
37. Förster GJ, et al. SPET/CT image co-registration in the abdomen with a
simple and cost-effective tool. European journal of nuclear medicine and
molecular imaging. 2003;30(1):32–9.
38. Bodei L, et al. Long-term tolerability of PRRT in 807 patients with
neuroendocrine tumours: the value and limitations of clinical factors. European
journal of nuclear medicine and molecular imaging. 2015;42(1):5–19.
39. Bergsma H, et al. Subacute haematotoxicity after PRRT with 177 Lu-DOTA-
octreotate: prognostic factors, incidence and course. European journal of
nuclear medicine and molecular imaging. 2016;43(3):453–63.
40. Walrand S, et al. Experimental facts supporting a red marrow uptake due to
radiometal transchelation in 90 Y-DOTATOC therapy and relationship to the
decrease of platelet counts. European journal of nuclear medicine and
molecular imaging. 2011;38(7):1270–80.
41. Sanchez-Garcia M, et al. Implementation and validation of collapsed cone
superposition for radiopharmaceutical dosimetry of photon emitters. Physics
in Medicine & Biology. 2015;60(20):7861.
42. Sanchez-Garcia M, et al. A new approach for dose calculation in targeted
radionuclide therapy (TRT) based on collapsed cone superposition:
validation with 90Y. Physics in Medicine & Biology. 2014;59(17):4769.
43. Shah AP, et al. A paired-image radiation transport model for skeletal
dosimetry. Journal of Nuclear Medicine. 2005;46(2):344–53.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
